The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...

Eli Lilly and Company has announced new long-term data from the ADjoin extension study, demonstrating that EBGLYSS ...

EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

(RTTNews) - Eli Lilly and Company (LLY) Wednesday reported new long-term data for its atopic dermatitis treatment Ebglyss. The results were reported from ADjoin long-term extension study.

The Federal Food and Drug Administration (FDA) has recently approved Eli Lilly’s EBGLYSS as a treatment for moderate-to-severe atopic dermatitis (eczema). EBGLYSS is now approved for adults and ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Eli Lilly presents promising long-term data showing Ebglyss' efficacy in treating moderate-to-severe atopic dermatitis, with over 80% of patients maintaining clear skin for up to three years. FDA and ...

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term ...

Eli Lilly has received approval in Japan for Kisunla (donanemab-azbt) to treat early symptomatic Alzheimer's disease.

In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...